Withdrawal of inhaled corticosteroids in COPD
- PMID: 32646895
- DOI: 10.1183/13993003.01778-2020
Withdrawal of inhaled corticosteroids in COPD
Conflict of interest statement
Conflict of interest: J.D. Chalmers has received speaker fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed; consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Insmed and Zambon; and holds research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols and Novartis. Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis, Sanofi and Grifols; and research grants from GlaxoSmithKline and Grifols.
Comment on
-
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline.Eur Respir J. 2020 Jun 4;55(6):2000351. doi: 10.1183/13993003.00351-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32366483
-
Withdrawal of inhaled corticosteroids in COPD.Eur Respir J. 2020 Jul 9;56(1):2001684. doi: 10.1183/13993003.01684-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32646894 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical